JMP Securities downgraded Sana Biotechnology (SANA) to Market Perform from Outperform without a price target after the company announced a portfolio reprioritization. The firm cites uncertainty associated with the company’s various data readouts for the downgrade. It now sees Sana shares as fairly valued.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.